Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ECHNO 2023 | The role of quality of life in the management of head and neck cancer

Paolo Bossi • 27 Mar 2023
ECHNO 2023
Head and Neck Cancer

Paolo Bossi, MD, University of Brescia, Brescia, Italy, talks on the role of quality of life (QoL) in the diagnosis and treatment of patients with head and neck cancer. Dr Bossi discusses the prognostic value of QoL, the importance of QoL in clinical trials, new research into underlying biological mechanisms that affect QoL, and the limitations of QoL assessment methods. This interview took place at the 2023 European Congress on Head and Neck Oncology (ECHNO) in Lisbon, Portugal.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Paolo Bossi

The future role of immunotherapy in head and neck cancer
1:37
The future role of immunotherapy in head and neck cancer
Paolo Bossi • 27 Mar 2023
HPV status, artificial intelligence, and IO in head and neck cancer
2:09
HPV status, artificial intelligence, and IO in head and neck cancer
Paolo Bossi • 27 Mar 2023
Reducing oral mucositis in patients treated with CRT using avasopasem manganese
1:25
Reducing oral mucositis in patients treated with CRT using avasopasem manganese
Paolo Bossi • 5 Jun 2022
Resistance to immune checkpoint blockade in patients with cSCC
1:20
Resistance to immune checkpoint blockade in patients with cSCC
Paolo Bossi • 5 Jun 2022

Related Videos

IMRT deintensification in early-stage oropharyngeal cancer: insights from the JCOG1208 trial
0:34
IMRT deintensification in early-stage oropharyngeal cancer: insights from the JCOG1208 trial
Satoaki Nakamura • 16 May 2026
Considerations for HPV status in the JCOG1208 trial of IMRT in early-stage oropharyngeal cancer
0:41
Considerations for HPV status in the JCOG1208 trial of IMRT in early-stage oropharyngeal cancer
Satoaki Nakamura • 16 May 2026
Can IMRT alone be used for higher-risk oropharyngeal cancer?
0:42
Can IMRT alone be used for higher-risk oropharyngeal cancer?
Satoaki Nakamura • 16 May 2026
Could cemiplimab replace HHI therapy in BCCHN?
0:36
Could cemiplimab replace HHI therapy in BCCHN?
Hannah Kenny • 30 May 2026

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJOncology is intended for healthcare professionals